Biospecimen Core

NIH RePORTER · NIH · P50 · $226,988 · view on reporter.nih.gov ↗

Abstract

CORE C: ABSTRACT Prospective procurement of biologic samples from prostate cancer patients along with accurate and detailed clinical and pathological data is key to the success of translational research, and its ultimate goal of improvement in the early detection, diagnosis and treatment of prostate cancer. SPORE sample procurement encompasses the rapid collection and storage of frozen tissue, blood (serum, plasma, peripheral blood mononuclear cells, and blood spots) and urine. Corresponding formalin-fixed paraffin-embedded (FFPE) tissue is available on each case, and biopsies are available in many cases as well (including some metastatic cases). In the SPORE renewal, the Biospecimen Pathology Core will continue with the following Specific Aims: Specific Aim 1: Prospective procurement and storage of human prostate tissue and other samples and associated data from consented patients at Northwestern University (NU) and University of Chicago (UC) hospital affiliates, in accordance with IRB regulations: a. Freshly frozen prostate tissue, including malignant, premalignant and benign tissues b. Serum, plasma and blood samples c. Urine d. Prostatic fluid (as needed) e. Prostate needle biopsies f. Archived formalin-fixed paraffin-embedded (FFPE) tissues g. Genomic DNA isolation from whole blood Specific Aim 2: To provide high quality histopathology review and quality control of specimens and pathology data with entry into the centralized SPORE database Specific Aim 3: To distribute well annotated samples to investigators conducting translational research after approval by the IRB and SPORE Tissue Review and Disbursement Committee. Specific Aim 4: To support SPORE projects and other translational research activities through histology, immunohistochemistry, laser capture microscopy, DNA and RNA preparation, and other specialized services on human and mouse tissues, including advanced immunophenotyping in conjunction with the Immune Assessment Cores at NU and UC. Specific Aim 5: To develop an innovative cfDNA hydroxymethylation assay that will support clinical trial activities associated with SPORE Projects

Key facts

NIH application ID
10895353
Project number
5P50CA180995-09
Recipient
NORTHWESTERN UNIVERSITY
Principal Investigator
XIMING J YANG
Activity code
P50
Funding institute
NIH
Fiscal year
2024
Award amount
$226,988
Award type
5
Project period
2015-08-18 → 2026-07-31